Bone Biologics Corporation

Equities

BBLG

US0980705018

Medical Equipment, Supplies & Distribution

Delayed Nasdaq Other stock markets 14:22:38 2024-07-17 EDT			5-day change	1st Jan Change
1.156 ^USD	+0.56%		+2.40%	-74.17%

06-20	Bone Biologics Corporation Announces First Two Patients Treated in Pilot Clinical Study with Bone Biologics NB1 Bone Graft Device in Spine Fusion	CI
05-14	Bone Biologics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Bone Biologics Corporation Reports Earnings Results for the Full Year Ended December 31, 2019

March 30, 2020 at 06:08 am

Bone Biologics Corporation announced earnings results for the full year ended December 31, 2019. For the full year, the company announced operating loss was USD 2.447 million compared to USD 2.790 million a year ago. Net loss was USD 3.424 million compared to USD 4.430 million a year ago. Basic loss per share from continuing operations was USD 0.47 compared to USD 0.88 a year ago.

Latest news about Bone Biologics Corporation

Bone Biologics Corporation Announces First Two Patients Treated in Pilot Clinical Study with Bone Biologics NB1 Bone Graft Device in Spine Fusion	06-20	CI
Bone Biologics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
Certain Common Stock of Bone Biologics Corporation are subject to a Lock-Up Agreement Ending on 4-MAY-2024.	05-03	CI
Certain Warrants of Bone Biologics Corporation are subject to a Lock-Up Agreement Ending on 4-MAY-2024.	05-03	CI
Certain Stock Options of Bone Biologics Corporation are subject to a Lock-Up Agreement Ending on 4-MAY-2024.	05-03	CI
Bone Biologics Corporation Reports Progress with NB1 Clinical Program	03-01	CI
Bone Biologics Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	02-21	CI
Bone Biologics Corporation Announces Board Changes	01-11	CI
Bone Biologics Corporation Announces the Resignation of Erick Lucera as Director	01-02	CI
Bone Biologics' 1-for-8 Reverse Stock Split Takes Effect Wednesday	12-18	MT
Bone Biologics Closes Common Stock Offering; Shares Fall After Hours	11-20	MT
Bone Biologics Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Bone Biologics Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Top Midday Decliners	23-06-15	MT
Top Premarket Decliners	23-06-15	MT
Bone Biologics Prices Underwritten Public Offering of Common Stock	23-06-15	MT
Bone Biologics Files Registration for Planned Stock Offering at Target Price of $5.40 a Share	23-06-07	MT
Bone Biologics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Certain Warrants of Bone Biologics Corporation are subject to a Lock-Up Agreement Ending on 6-APR-2023.	23-04-05	CI
Certain Options of Bone Biologics Corporation are subject to a Lock-Up Agreement Ending on 6-APR-2023.	23-04-05	CI
Certain Common Stock of Bone Biologics Corporation are subject to a Lock-Up Agreement Ending on 6-APR-2023.	23-04-05	CI
Bone Biologics Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
Bone Biologics Corporation Auditor Raises 'Going Concern' Doubt	23-03-29	CI
Top Premarket Decliners	23-03-22	MT
Bone Biologics Corporation Resigns Stephen Laneve as Director	22-12-21	CI

Chart Bone Biologics Corporation

Duration

Period

More charts

Company Profile

Bone Biologics Corporation is a developer of orthobiologic products for spine fusion markets. It is focusing development efforts for its bone graft substitute product on bone regeneration in spinal fusion procedures, while additionally having rights to trauma and osteoporosis applications. It is a medical device company that is focused on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1. NELL-1 in combination with demineralized bone matrix (DBM), is an osteopromotive recombinant protein that provides target specific control over bone regeneration. Its platform technology is its NELL-1, a proprietary skeletal specific growth factor which is a bone void filler. NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration. The DBM Demineralized Bone Putty provided as part of the convenience kit with NELL-1/DBM is a Class II device. DBM Putty is a matrix composed of processed human cortical bone.

Sector

Medical Equipment, Supplies & Distribution

More about the company

Sector Medical Devices & Implants

	1st Jan change	Capi.
BONE BIOLOGICS CORPORATION	-74.17%	1.27M
STRYKER CORPORATION	+12.52%	127B
SMITH & NEPHEW PLC	+0.97%	12B
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.	-18.47%	6.88B
GLAUKOS CORPORATION	+56.13%	6.86B
AXONICS, INC.	+9.28%	3.47B
ENOVIS CORPORATION	-15.73%	2.54B
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD.	-18.25%	1.9B
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD.	-27.00%	1.58B
DOUBLE MEDICAL TECHNOLOGY INC.	-37.52%	1.43B

Medical Devices & Implants